Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate.

The American journal of drug and alcohol abuse - 1 Jan 2018

Crist Richard C, Li James, Doyle Glenn A, Gilbert Alex, Dechairo Bryan M, Berrettini Wade H

Abstract excerpt

BACKGROUND: Currently, no pharmacogenetic tests for selecting an opioid-dependence pharmacotherapy have been approved by the US Food and Drug Administration. OBJECTIVES: Determine the effects of variants in 11 genes on dropout rate and dose in patients receiving methadone or buprenorphine/naloxone (ClinicalTrials.gov Identifier: NCT00315341). METHODS: Variants in six pharmacokinetic genes (CYP1A2, CYP2B6,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to OPRM1 gene
Share to Genotype
Share to Methadone

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Narcotic Antagonists

Share to Opioid-Related Disorders

Share to Pharmacogenetics

Share to Pharmacogenomic Testing

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 29333880
DOI: 10.1080/00952990.2017.1420795
PMCID: PMC5940523

Genes

COMT
OPRM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate.PMID 29333880Read ↗

Pharmacogenetics of Opioid Use Disorder Treatment.Semantic proximity Read ↗

A review of the existing literature on buprenorphine pharmacogenomics.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy.Semantic proximity Read ↗

Pharmacogenomics of methadone: a narrative review of the literature.Semantic proximity Read ↗

[Pharmacogenetics and the treatment of addiction].Semantic proximity Read ↗

A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder.Semantic proximity Read ↗

ABCB1, SLC22A1, COMT, and OPRM1 genotypes: Study of their influence on plasma methadone levels and clinical response to methadone maintenance treatment in opioid use disorder.Semantic proximity Read ↗

Genome-Wide Pharmacogenomic Study on Methadone Maintenance Treatment Identifies SNP rs17180299 and Multiple Haplotypes on CYP2B6, SPON1, and GSG1L Associated with Plasma Concentrations of Methadone R- and S-enantiomers in Heroin-Dependent Patients.Semantic proximity Read ↗

Pharmacogenomics and Opioid Use Disorder: Clinical Decision Support in an African American Cohort.Semantic proximity Read ↗

OPRM1 and CYP3A4 association with methadone dose in Iranian patients undergoing methadone maintenance therapy.Semantic proximity Read ↗

Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity.Semantic proximity Read ↗

Pharmacogenetic treatments for drug addiction: alcohol and opiates.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.